Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190584 | 0.87 | LMNA (0.42) | LMNAKMT2AHTTTP53 | |
| SCHEMBL5634184 | 0.76 | GAA (0.42) | LMNAHTTHSD17B10TP53 | |
| SCHEMBL30753921 | 0.72 | LMNA (0.37) | LMNAKMT2AL3MBTL1HSD17B10DNM1 | |
| SCHEMBL15432263 | 0.72 | CHRNB2 (0.38) | SCN9A | |
| SCHEMBL7397131 | 0.71 | SCN9A (0.34) | LMNASCN9AHSD17B10 | |
| SCHEMBL17560422 | 0.71 | CHRNB2 (0.42) | L3MBTL1SCN9A | |
| SCHEMBL5634652 | 0.71 | L3MBTL1 (0.46) | KMT2AL3MBTL1HSD17B10 | |
| SCHEMBL1381187 | 0.71 | ALDH1A1 (0.49) | LMNAKMT2AL3MBTL1HTT | |
| SCHEMBL31413299 | 0.71 | LMNA (0.43) | LMNAL3MBTL1HSD17B10TP53 | |
| SCHEMBL31403471 | 0.70 | DNM1 (0.38) | LMNAKMT2AL3MBTL1HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | LMNA 976/4885KMT2A 396/4885L3MBTL1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.